Results 41 to 50 of about 224,706 (187)

Aggravated Orbitopathy Following Remnant Ablation in a Patient with Multiple Cancers

Endocrinology Research and Practice, 2017
The rate of thyroid cancer in the patients with Graves’ disease is controversial. The rare incidents of multiple primary thyroid cancers in the same patient have been reported.
Umut MOUSA, Hasan SAV, Osman KÖSEOĞULLARI, Şebnem AYDIN, Hanife ÖZKAYALAR   +4 more
doaj   +1 more source

The change in the clinical presentation of Graves’ disease: a 30 years retrospective survey in an academic Brazilian tertiary center

Archives of Endocrinology and Metabolism, 2020
Objective Graves’ disease (GD) is the main cause of hyperthyroidism among adults. It is an autoimmune condition classically marked by the Merserburg Triad (goiter, thyrotoxicosis, and orbitopathy), but the change in presentation of GD over time has ...
Wanesa Pinto, João H. Romaldini, Nicolas Perini, Roberto B. Santos, Danilo Villagelin   +4 more
doaj   +1 more source

Natural history of graves’ orbitopathy after treatment

, 2016
Intravenous glucocorticoids are used for Graves’ orbitopathy, alone or associated with/followed by additional treatments (orbital radiotherapy, orbital decompression, palpebral or eye surgery).
SELLARI FRANCESCHINI, STEFANO, MARINO', MICHELE, MENCONI, FRANCESCA, LEO, MARENZA, NARDI, MARCO, SABINI, ELENA, Sainato, Aldo, VITTI, PAOLO, MAUTONE, TERESA, MARCOCCI, CLAUDIO   +9 more
core   +1 more source

The role of pain in Graves' orbitopathy: Associations with clinical activity and quality of life

Acta Ophthalmologica, EarlyView.
Abstract Purpose Pain is included in the clinical activity score (CAS) as an indicator of inflammatory activity in Graves' orbitopathy (GO), yet its clinical relevance has not been systematically evaluated. We therefore investigated the relationship between pain, other inflammatory signs and quality of life (QoL), and assessed the effect of intravenous
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, Marco Medici, Maaike de Bie, P. Martin van Hagen, Dion Paridaens   +7 more
wiley   +1 more source

Current Knowledge on Graves’ Orbitopathy [PDF]

Journal of Clinical Medicine, 2020
(1) Background: Graves’ orbitopathy (GO) is an autoimmune inflammation of the orbital tissues and the most common extra-thyroid symptom of Graves’ disease (GD). Mild cases of GO are often misdiagnosed, which prolongs the diagnostic and therapeutic process, leading to exacerbation of the disease. A severe course of GO may cause permanent vision loss. (2)
Katarzyna Gontarz-Nowak, Magdalena Szychlińska, Wojciech Matuszewski, Magdalena Stefanowicz-Rutkowska, Elżbieta Bandurska-Stankiewicz   +4 more
openaire   +2 more sources

Isolated primary amyloidosis of the inferior rectus muscle mimicking Graves’ orbitopathy

Einstein (São Paulo)
The diagnosis of Graves’ orbitopathy is usually straightforward. However, orbital diseases that mimick some clinical signs of Graves’ orbitopathy may cause diagnostic confusion, particularly when associated to some form of thyroid dysfunction.
Mário Luiz Ribeiro Monteiro, Allan Christian Pieroni Gonçalves, Alanna Mara Pinheiro Sobreira Bezerra   +2 more
doaj   +1 more source

The relation between clinical response and quality of life improvement after treatment with intravenous methylprednisolone in Graves' orbitopathy

Acta Ophthalmologica, EarlyView.
Abstract Background Quality of life (QoL) is a key outcome in Graves' orbitopathy (GO), but prior studies have reported overall QoL changes without evaluating whether improvements occur specifically in patients who achieve objective clinical response.
Gijsbert J. Hötte, Willem A. Dik, Ronald O. B. de Keizer, Sodaba Khatab, M. Medici, Sigrid M. A. Swagemakers, Peter J. van der Spek, P. Martin van Hagen, Dion Paridaens   +8 more
wiley   +1 more source

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' Orbitopathy

, 2016
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease.
Bartalena, Luigi, Eckstein, Anja, Kahaly, George J., Salvi, Mario, Marcocci, Claudio, On behalf of the European Group on Graves'' Orbitopathy (EUGOGO), Dayan, Colin Mark, Perros, Petros, European Group on Graves' Orbitopathy (EUGOGO), Baldeschi, Lelio, Boboridis, Kostas, Wiersinga, Wilmar M   +11 more
core   +1 more source

Graves' orbitopathy treated with immunosuppressive therapy and orbital radiotherapy in a tertiary care endocrine centre: case series

Sri Lanka Journal of Diabetes Endocrinology and Metabolism, 2016
Graves’ Orbitopathy (GO) is a localized entity of Graves’ disease, which is a challenging disease to treat. We describe 6 cases of moderate to severe GO who presented to our endocrine centre, with a mean age of 48.6 years and equal gender distribution ...
D. C. Kottahachchi, W. K. M. G. Amarawardena, N. A. S. Ariyawansa, S. Siyambalapitiya, K. A. Perera   +4 more
doaj   +1 more source

Diagnostic Options in Graves' or Non‐Graves' Thyrotoxicosis: A Review for Clinical Practice

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Distinguishing Graves' disease (GD) from the other causes of thyrotoxicosis is essential for appropriate management. The clinical phenotype of GD has evolved over time and is currently more heterogenous and milder than in the past. Consequently, the differential diagnosis of thyrotoxicosis is often challenging.
Lorenzo Scappaticcio, Pierpaolo Trimboli, Paola Caruso, Chiara Porcellini, Daniela Forestiere, Maria Ida Maiorino, Katherine Esposito, Giuseppe Bellastella   +7 more
wiley   +1 more source